ZA200304994B - Piperazine derivatives, their preparation and their use for treating central nervous systems (CNS) disorders. - Google Patents
Piperazine derivatives, their preparation and their use for treating central nervous systems (CNS) disorders. Download PDFInfo
- Publication number
- ZA200304994B ZA200304994B ZA200304994A ZA200304994A ZA200304994B ZA 200304994 B ZA200304994 B ZA 200304994B ZA 200304994 A ZA200304994 A ZA 200304994A ZA 200304994 A ZA200304994 A ZA 200304994A ZA 200304994 B ZA200304994 B ZA 200304994B
- Authority
- ZA
- South Africa
- Prior art keywords
- compound
- composition
- substance
- pharmaceutically acceptable
- patient
- Prior art date
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims description 8
- 150000004885 piperazines Chemical class 0.000 title description 2
- 229940066771 systemic antihistamines piperazine derivative Drugs 0.000 title description 2
- 210000003169 central nervous system Anatomy 0.000 title 2
- 150000001875 compounds Chemical class 0.000 claims description 120
- 239000000203 mixture Substances 0.000 claims description 59
- 239000000126 substance Substances 0.000 claims description 55
- 238000000034 method Methods 0.000 claims description 45
- 150000003839 salts Chemical class 0.000 claims description 45
- 239000003814 drug Substances 0.000 claims description 18
- 239000002253 acid Substances 0.000 claims description 14
- 208000010877 cognitive disease Diseases 0.000 claims description 8
- -1 piperazine compound Chemical class 0.000 claims description 8
- 208000035475 disorder Diseases 0.000 claims description 6
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- 206010003805 Autism Diseases 0.000 claims description 4
- 208000020706 Autistic disease Diseases 0.000 claims description 4
- 208000018737 Parkinson disease Diseases 0.000 claims description 4
- 230000002152 alkylating effect Effects 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 4
- 229910052736 halogen Chemical group 0.000 claims description 4
- 150000002367 halogens Chemical group 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 claims description 3
- 208000019901 Anxiety disease Diseases 0.000 claims description 3
- 208000030814 Eating disease Diseases 0.000 claims description 3
- 208000017701 Endocrine disease Diseases 0.000 claims description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 3
- 208000019454 Feeding and Eating disease Diseases 0.000 claims description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 3
- 208000019695 Migraine disease Diseases 0.000 claims description 3
- 201000001880 Sexual dysfunction Diseases 0.000 claims description 3
- 206010041250 Social phobia Diseases 0.000 claims description 3
- 208000000323 Tourette Syndrome Diseases 0.000 claims description 3
- 208000016620 Tourette disease Diseases 0.000 claims description 3
- 206010046543 Urinary incontinence Diseases 0.000 claims description 3
- 230000036506 anxiety Effects 0.000 claims description 3
- 208000015114 central nervous system disease Diseases 0.000 claims description 3
- 235000014632 disordered eating Nutrition 0.000 claims description 3
- 206010027599 migraine Diseases 0.000 claims description 3
- 229960002715 nicotine Drugs 0.000 claims description 3
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 claims description 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 201000000980 schizophrenia Diseases 0.000 claims description 3
- 231100000872 sexual dysfunction Toxicity 0.000 claims description 3
- 208000019116 sleep disease Diseases 0.000 claims description 3
- 230000001331 thermoregulatory effect Effects 0.000 claims description 3
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 3
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims description 2
- 229940100198 alkylating agent Drugs 0.000 claims description 2
- 239000002168 alkylating agent Substances 0.000 claims description 2
- 150000001408 amides Chemical class 0.000 claims description 2
- 150000007514 bases Chemical class 0.000 claims description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N diethylenediamine Natural products C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 claims description 2
- AEOCXXJPGCBFJA-UHFFFAOYSA-N ethionamide Chemical compound CCC1=CC(C(N)=S)=CC=N1 AEOCXXJPGCBFJA-UHFFFAOYSA-N 0.000 claims description 2
- 150000004820 halides Chemical class 0.000 claims description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 claims description 2
- NRPQELCNMADTOZ-OAQYLSRUSA-N 4-cyano-n-[(2r)-2-[4-(2,3-dihydro-1,4-benzodioxin-5-yl)piperazin-1-yl]propyl]-n-pyridin-2-ylbenzamide Chemical compound C([C@@H](C)N1CCN(CC1)C=1C=2OCCOC=2C=CC=1)N(C=1N=CC=CC=1)C(=O)C1=CC=C(C#N)C=C1 NRPQELCNMADTOZ-OAQYLSRUSA-N 0.000 claims 3
- 208000026139 Memory disease Diseases 0.000 claims 2
- 208000019430 Motor disease Diseases 0.000 claims 2
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 208000013403 hyperactivity Diseases 0.000 claims 2
- NRPQELCNMADTOZ-UHFFFAOYSA-N 4-cyano-n-[2-[4-(2,3-dihydro-1,4-benzodioxin-5-yl)piperazin-1-yl]propyl]-n-pyridin-2-ylbenzamide Chemical compound C1CN(C=2C=3OCCOC=3C=CC=2)CCN1C(C)CN(C=1N=CC=CC=1)C(=O)C1=CC=C(C#N)C=C1 NRPQELCNMADTOZ-UHFFFAOYSA-N 0.000 claims 1
- ASXGJMSKWNBENU-UHFFFAOYSA-N 8-OH-DPAT Chemical compound C1=CC(O)=C2CC(N(CCC)CCC)CCC2=C1 ASXGJMSKWNBENU-UHFFFAOYSA-N 0.000 description 14
- 125000000217 alkyl group Chemical group 0.000 description 14
- 230000004044 response Effects 0.000 description 9
- 239000000556 agonist Substances 0.000 description 8
- 239000005557 antagonist Substances 0.000 description 8
- 125000003118 aryl group Chemical group 0.000 description 8
- 239000007788 liquid Substances 0.000 description 8
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 230000009471 action Effects 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- 239000000651 prodrug Substances 0.000 description 6
- 229940002612 prodrug Drugs 0.000 description 6
- 239000004480 active ingredient Substances 0.000 description 5
- 239000000969 carrier Substances 0.000 description 5
- 125000000753 cycloalkyl group Chemical group 0.000 description 5
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 5
- 229940126062 Compound A Drugs 0.000 description 4
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 4
- 125000001072 heteroaryl group Chemical group 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 230000003389 potentiating effect Effects 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 239000003981 vehicle Substances 0.000 description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 229910052739 hydrogen Inorganic materials 0.000 description 3
- 239000001257 hydrogen Substances 0.000 description 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 238000007911 parenteral administration Methods 0.000 description 3
- 239000002464 receptor antagonist Substances 0.000 description 3
- 229940044551 receptor antagonist Drugs 0.000 description 3
- IUVCFHHAEHNCFT-INIZCTEOSA-N 2-[(1s)-1-[4-amino-3-(3-fluoro-4-propan-2-yloxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]ethyl]-6-fluoro-3-(3-fluorophenyl)chromen-4-one Chemical compound C1=C(F)C(OC(C)C)=CC=C1C(C1=C(N)N=CN=C11)=NN1[C@@H](C)C1=C(C=2C=C(F)C=CC=2)C(=O)C2=CC(F)=CC=C2O1 IUVCFHHAEHNCFT-INIZCTEOSA-N 0.000 description 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
- 206010012289 Dementia Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 230000006835 compression Effects 0.000 description 2
- 238000007906 compression Methods 0.000 description 2
- PAFZNILMFXTMIY-UHFFFAOYSA-N cyclohexylamine Chemical group NC1CCCCC1 PAFZNILMFXTMIY-UHFFFAOYSA-N 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000005714 functional activity Effects 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 208000027061 mild cognitive impairment Diseases 0.000 description 2
- 125000002950 monocyclic group Chemical group 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000008174 sterile solution Substances 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- HFVMEOPYDLEHBR-UHFFFAOYSA-N (2-fluorophenyl)-phenylmethanol Chemical compound C=1C=CC=C(F)C=1C(O)C1=CC=CC=C1 HFVMEOPYDLEHBR-UHFFFAOYSA-N 0.000 description 1
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- MVPHZNURHVHIMM-UHFFFAOYSA-N 1-(1,4-benzodioxin-3-yl)piperazine Chemical compound C1CNCCN1C1=COC2=CC=CC=C2O1 MVPHZNURHVHIMM-UHFFFAOYSA-N 0.000 description 1
- VNZLQLYBRIOLFZ-UHFFFAOYSA-N 1-(2-methoxyphenyl)piperazine Chemical compound COC1=CC=CC=C1N1CCNCC1 VNZLQLYBRIOLFZ-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- QISOBCMNUJQOJU-UHFFFAOYSA-N 4-bromo-1h-pyrazole-5-carboxylic acid Chemical compound OC(=O)C=1NN=CC=1Br QISOBCMNUJQOJU-UHFFFAOYSA-N 0.000 description 1
- USEDMAWWQDFMFY-UHFFFAOYSA-N 4-cyanobenzoyl chloride Chemical compound ClC(=O)C1=CC=C(C#N)C=C1 USEDMAWWQDFMFY-UHFFFAOYSA-N 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- PXRKCOCTEMYUEG-UHFFFAOYSA-N 5-aminoisoindole-1,3-dione Chemical compound NC1=CC=C2C(=O)NC(=O)C2=C1 PXRKCOCTEMYUEG-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 235000003911 Arachis Nutrition 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 208000032841 Bulimia Diseases 0.000 description 1
- 206010006550 Bulimia nervosa Diseases 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 208000020401 Depressive disease Diseases 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 102100028701 General vesicular transport factor p115 Human genes 0.000 description 1
- 208000011688 Generalised anxiety disease Diseases 0.000 description 1
- 101000767151 Homo sapiens General vesicular transport factor p115 Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 206010033664 Panic attack Diseases 0.000 description 1
- 206010033864 Paranoia Diseases 0.000 description 1
- 208000027099 Paranoid disease Diseases 0.000 description 1
- 208000028017 Psychotic disease Diseases 0.000 description 1
- 229940121991 Serotonin and norepinephrine reuptake inhibitor Drugs 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric Acid Chemical compound [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 208000030886 Traumatic Brain injury Diseases 0.000 description 1
- 206010047163 Vasospasm Diseases 0.000 description 1
- 150000008065 acid anhydrides Chemical class 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 125000002947 alkylene group Chemical group 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- PASDCCFISLVPSO-UHFFFAOYSA-N benzoyl chloride Chemical compound ClC(=O)C1=CC=CC=C1 PASDCCFISLVPSO-UHFFFAOYSA-N 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 238000013262 cAMP assay Methods 0.000 description 1
- 230000003491 cAMP production Effects 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 150000001722 carbon compounds Chemical class 0.000 description 1
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000012059 conventional drug carrier Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- WZHCOOQXZCIUNC-UHFFFAOYSA-N cyclandelate Chemical compound C1C(C)(C)CC(C)CC1OC(=O)C(O)C1=CC=CC=C1 WZHCOOQXZCIUNC-UHFFFAOYSA-N 0.000 description 1
- 125000000392 cycloalkenyl group Chemical group 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 238000000921 elemental analysis Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- DSLZVSRJTYRBFB-DUHBMQHGSA-N galactaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C(O)=O DSLZVSRJTYRBFB-DUHBMQHGSA-N 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 208000029364 generalized anxiety disease Diseases 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 235000015220 hamburgers Nutrition 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 150000007928 imidazolide derivatives Chemical class 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 210000004558 lewy body Anatomy 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 230000031868 operant conditioning Effects 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 239000012057 packaged powder Substances 0.000 description 1
- WLJNZVDCPSBLRP-UHFFFAOYSA-N pamoic acid Chemical compound C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 WLJNZVDCPSBLRP-UHFFFAOYSA-N 0.000 description 1
- 208000019906 panic disease Diseases 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 229920006316 polyvinylpyrrolidine Polymers 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000002287 radioligand Substances 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 239000002868 serotonin 5-HT1 receptor antagonist Substances 0.000 description 1
- 239000003775 serotonin noradrenalin reuptake inhibitor Substances 0.000 description 1
- 239000003762 serotonin receptor affecting agent Substances 0.000 description 1
- 239000003772 serotonin uptake inhibitor Substances 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 230000009529 traumatic brain injury Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
® WO 02/44142 PCT/US01/43160
SEROTONERGIC AGENTS
This invention relates to novel piperazine derivatives, to their use and to pharmaceutical compositions containing them. The novel compounds are useful as 5-
HT 4a binding agents, particularly as 5-HT4 a receptor antagonists.
U.S. Patent No. 6,127,357 discloses compounds of the general formula (1):
R
/ N Fe
RN N=A=N
CZR; (1) and pharmaceutically acceptable acid addition salts thereof wherein:
A is alkylene chain of 2 to 4 carbon atoms optionally substituted by one or more lower alkyl groups,
Z is oxygen or sulfur,
Ris H or lower alkyl,
R1 is a mono or bicyclic aryl or heteroaryl radical,
R2 is a mono or bicyclic heteroaryl radical, and
R3 is hydrogen, lower alkyl, cycloalkyl, cycloalkenyl, cycloalkyl(lower)alkyl, aryl, aryl(lower)alkyl, heteroaryl, heteroaryl(lower)alkyl, a group of formula -NR4RS [where
R4 is hydrogen, lower alkyl, aryl or aryl(lower)alkyl and RS is hydrogen, lower alkyl, -CO(lower)alkyl, aryl, -Coaryl, aryl(lowerjalkyl, cycloalkyl, or cycloalkyl-(lower)alkyl or
R4 and RS together with the nitrogen atom to which they are both attached represent a saturated hytrocyclic ring which may contain a further heteroatom], or a group of formula OR® [where R6 is lower alkyl, cycloalkyl, cycloalkyl(lowerjalkyl, aryl, ! aryl(lower)alkyl, heteroaryl or heteroaryl(lower)alkyl].
® WO 02/44142 PCT/US01/43160 ~~
CH, —=N 1
AN s ) o ’
O . oJ (mn including enantiomers and the pharmaceutically acceptable acid addition salts thereof.
The compounds of formula (11) fall within the disclosure of U.S. Patent No. 6,127,357 but are not specifically disclosed therein. Compounds of Formula Il were taught to have potent 5-HT{p antagonist activity in vivo when administered by the oral route.
Novel compounds of the invention have the stryctural formula (ll):
A
CH. ~N Rq
Or 0 (my ‘ wherein R, is cyano, nitro, trifluoromethyl or halogen, or pharmaceutically acceptable acid addition salts thereof.
Halogen, as used herein, refers to chlorine, fluorine, bromine and iodine. f
The compounds of Formula Ill contain an asymmetric carbon atom.
Accordingly, they may exist in different stereoisomeric forms or mixtures thereof 4
I
® WO 02/44142 PCT/US01/43160 including racemates. In some preferred embodiments the R stereoisomer (Formula ) Illa) is preferred.
Xo
LO Ri (9 ELT or o)
Formula llla
In accordance with some embodiments of the invention, the (R) stereoisomer is in enantiomeric excess of the (S) stereoisomer. Preferably the compound is made up of a significantly greater proportion of its (R) stereoisomer than the (S) stereoisomer. In preferred embodiments the compound is made up of at least about 90% by weight of its (R) stereoisomer and about 10% by weight or less of its (S) sterecisomer. In other embodiments of the invention, the compound is made up of at least about 99% by weight of its (R) sterecisomer and about 1% by weight or less of the (S) stereoisomer, e.g. substantially free from (S)-stereoisomer, most preferably substantially pure or pure (R) stereoisomer. Preferred stereoisomers may be isolated from racemic mixtures by any method known to those skilled in the art, including high performance liquid chromatography (HPLC) and the formation and crystallization of chiral salts. See, for example, Jacques, et al., Enantiomers, Racemates and
Resolutions (Wiley Interscience, New York, 1981); Wilen, S.H., et al., Tetrahedron 33:2725 (1977); Eliel, E.L. Stereochemistry of Carbon Compounds (McGraw-Hill, NY, 1962); Wilen, S.H. Tables of Resolving Agents and Optical Resolutions p. 268 (E.L.
Eliel, Ed., Univ. of Notre Dame Press, Notre Dame, IN 1972).
The most preferred compounds of the invention are (R)-4-Cyano-N-{2-[4-(2,3- dihydro-benzo[1 ,4]dioxin-5-yl)-piperazin-1 -yllpropy!}-N-pyridin-2-yl-benzamide; and pharmaceutically acceptable acid addition salts thereof. \
The pharmaceutically acceptable salts are the acid addition salts which can be : formed from a compound of the above general formula and a pharmaceutically acceptable acid such as, for example, benzoic, phosphoric, sulfuric, hydrochloric,
® WO 02/44142 PCT/US01/43160 hydrobromic, citric, maleic, malic, mandelic, mucic, nitric, fumaric, succinic, tartaric, acetic, lactic, pamoic, pantothenic, benzenesulfonic, or methanesulfonic acid. In some embodiments of the invention the preferred acid addition salt is hydrochloric , acid. 5 .
The compounds of the present invention can be prepared by known methods from known starting materials which are available by conventional methods. For : example the compounds may be prepared by the general methods disclosed in EP-A- 0512755 and WO 97/03982. Accordingly this invention provides a process for preparing a compound of formula (Ill) which comprises one of the following: a) acylating a compound of formula (IV):
AN
CH ~N or (IV) using an acylating agent containing the moiety yey \ So wherein R; is as defined herein; or
Db) alkylating an amide or thioamide of formula (V1) [ —N w—n—co—{ Hs, r (vi) é
Q,, 02/44142 PCT/US01/43160 (where R, is defined above) with an alkylating agent (e.g halide or tosylate) providing the group of formula (VII)
Oo O
SN
N N—=C. _~ (vit) or c) alkylating a compound of formula (VIII 0 -- 0
N NH
CS _/
I
1) with a compound of formula (IX) x ~N
CHs
J noo Hr
X
(IX) (where R; is as defined above and X is a leaving group) or d) heteroarylating a compound of formula (X) : o Oo CH 7 \ wwe)
N N
(X) (where R; is as defined above) with a compound providing the 2-pyridyl group;
or e) reacting a piperazine compound of formula
Xx
ZN
Oh
HN v—L__n—co—/ rs (where R, is as defined above) with a fluoro compound of formula
Oo 0
Eo or f) converting a basic compound of formula (lll) as defined herein to a pharmaceutically acceptable acid addition salt thereof or vice versa; or g) resolving a racemic compound of formula (Ili) to give an enantiomeric excess of the R form over the S form, or vice versa. : 15
Such disclosed methods include acylating an amine of formula (IV) with a known benzoyl chloride (V) or an alternative acylating derivative thereof. Examples of acylating derivatives include the acid anhydride, imidazolides (e.g. obtained form carbonyldiimidazole), or activated esters.
AS
N
CH; YY (To Nr NH Ri or on LT © (Iv) V) wherein R, is cyano, halogen, trifluoromethyl or nitro.
r— WO 02/44142 PCT/US01/43160
Novel compounds of the present invention are potent 5-HT4 a binding agents which selectively bind to the 5-HT4 a receptor. Furthermore, the novel compounds of the invention are 5-HTqp receptor antagonists when tested by standard pharmacological procedures.
In addition, the novel compounds of formula (lll) are unique from previously disclosed SHT1A receptor antagonists in that they possess a superior duration of action as a 5-HT 1 receptor antagonist when administered in vivo.
The present invention is illustrated by reference to the following example.
Those skilled in the art of organic synthesis may be aware of still other synthetic routes to the invention compound. The reagents and intermediates used herein are either commercially available or prepared according to standard literature procedures.
EXAMPLE 1 (R)-4-Cyano-N-{2-[4-(2,3-Dihydro-Benzo[1,4]dioxin-5-yl)-Piperazin-1-yl}-
Propyl}-N-Pyridin-2-yl-Benzamide
A solution of {(R)-2-[4-(2,3-dihydrobenzo[1,4]dioxin-5-yl)piperazin-1-ylJpropyl}-pyridin- 2-ylamine (0.846 g, 2.38 mmol) in dichloromethane (20 mL) was treated at 0°C with the dropwise addition of a dichloromethane solution of 4-cyanobenzoyl chloride (1.1 equivalents, 2.63 mmol in 5 mL). After stirring for 16 hours the mixture was poured onto hexane (100 mL) to precipitate the titled compound as its mono- hydrochloride salt (white solid, 1.2 g, 97% yield), which was recrystallized from dichforomethane/- hexane.
MS (+) 484 (M + H)". m.p. 239-240°C [a] 25/D = + 56 (c = 0.6, MeOH)
Elemental Analysis for: CosH,0NsO3 » 1.0 HCI
Calculated: C, 64.67; H, 5.81; N, 13.47:
Found: C, 64.69; H, 5.93; N, 13.52:
JW 02/44142 PCT/US01/43160
In order to demonstrate the superior duration of action of the compounds of formula (ill), Example 1 was compared to representative compounds of U.S. Patent
No. 6,127,357 and WO 97/03892.
Representative compounds of U.S. Patent No. 6,127,357 possess a cyclo- hexylamide moiety and a 2-methoxyphenylpiperazine grouping. The most potent example of this general structure (and the most potent compound taught in U.S. -
Patent No. 6,127,357) is compound A, described as “example 3” in U.S. 6,127,357.
The only other class of compounds in U.S. 6,127,357 for which data are given is that which possess a cyclohexylamide moiety and a benzodioxinylpiperazine grouping (‘Example 17” in U.S. 6,127,357). A small subset of this class of compounds is specifically claimed in WO97/03892, with the preferred compound being compound B (‘example A1” in WO097/03892). Therefore, these two preferred examples from
EP-A-0512755 and WO 97/03892 have been chosen as representatives for 16 comparison to the compounds of formula (111). [ [ ~N CHs ~N
AN
NS 0 oA NA e or
Compound A Compound B (“Example 3" from U.S. 6,127357) (“Example A1” from WO 97/03892)
EXAMPLE 2
BINDING PROFILE
Compounds were tested for binding to cloned human 5-HT {A receptors stably transfected into CHO cells using [BH]8-OH-DPAT as the 5-HT4A radioligand (according to general procedure described in J. Dunlop et al., J. Pharmacol. Tox.
Methods, 40, 47-55 (1998)). As shown in Table 1, compounds of the present invention display high affinity for the S5SHT1A receptor. :
® WO 02/44142 PCT/US01/43160
EXAMPLE 3
IN VITRO FUNCTIONAL ACTIVITY
A clonal cell line stably transfected with the human 5-HT4p receptor was utilized to determine the intrinsic activity of compounds (according to the general procedure described in J. Dunlop et al, J. Pharmacol. Tox. Methods, 40, 47-55 (1998)). Data are provided in Table 1. As shown in Table 1, compounds of the present invention antagonized the ability of 10 nM 8-OH-DPAT to inhibit forskolin- stimulated cAMP production in a concentration-related fashion. | Table 1 cAMP Assay
Ki (nM) ICs0 (NM)
ComewdA | o% | T
Compeuna® | oo | mm
EXAMPLE 4
IN VIVO FUNCTIONAL ACTIVITY
The ability of the compounds to function in vivo as 5-HT 1a antagonists was assessed in rats using a Fixed Responding Model (D. Blackman, in “Operant Conditioning: An
Experimental Analysis of Behavior”, J. Butcher, ed., Methuen and Co., Ltd., London).
In this model rats are trained to respond (lever pressing) under a fixed-ratio 30 schedule of food presentation in order to receive a food pellet reinforcer.
Administration of the 5-HT 4a agonist 8-OH-DPAT reduces the control response rate (assessed by administration of vehicle placebo). The 5-HT4A antagonist activity of a test compound is determined by measuring its ability to antagonize this agonist- induced decrease in response rate. A full antagonist effect is considered one in which ' the test compound completely reverses the agonist-induced response rate, returning it to control levels. The data given in Table 2 demonstrate that a 1 mg/kg dose of the . compound of Example 1 completely reverses the decrease in response rate induced
® WO 02/44142 PCT/US01/43160 by administration of a 0.3 mg/kg dose of 8-OH-DPAT. Thus, compounds of the present invention function as 5-HTq a antagonists in vivo. v
Table 2
Vehicle 8-OH-DPAT 8-OH-DPAT (0.3 mg/kg sc)
EXAMPLE 5
DURATION OF ACTION IN VIVO CT ) I
The duration of action in the Fixed Responding Model was assessed by pre- treating animals with test compound and then challenging with a 0.3 mg/kg dose of the 5-HT4A agonist 8-OH-DPAT at various time intervals after the administration of test compound. All drug and vehicle administrations were made by the subcutaneous route. Doses of the test compounds selected for comparison were those which caused a ten-fold shift in the 8-OH-DPAT dose-response curve when administered 30 minutes prior to agonist. The doses selected for the duration of action comparison are listed in Table 3.
Table 3
Dose-response Curve by 10-fold (mg/kg, sc)
Data are presented for pre-treatment of the animals with test compound at 0.5 hours, 2 hours, and 4 hours prior to administration of a 0.3 mg/kg dose of 8-OH- !
DPAT. Results are normalized to control values, with 100% being the control response rate observed when vehicle is administered rather than the agonist 8-OH- .
DPAT.
Table 4
TT] % Response Rate
Compound 0.5 hour 2 hour 4 hour pretreatment pretreatment pretreatment
Compound A+ 90+£3 55+ 28 41+ 26 8-OH-DPAT
Control + 23+9 3+1 3x1 8-OH-DPAT
Compound B+ 100 + 11 71+12 27 +14 8-OH-DPAT
Control + 2119 42416 42 +6 el 8-OH-DPAT
Example 1 + 10017 118 £13 99 + 16 8-OH-DPAT
Control! + 29+6 35+ 10 35+ 10 8-OH-DPAT
As can be seen from Table 4, all three test compounds (Compound A, B and
Example 1) completely antagonize the agonist-induced decrease in responding 30 minutes after their administration, returning the response rate to control levels.
However, when agonist is given 2 hours following test drug administration (Column 3), the 5-HTqA antagonist effects of compounds A and B no longer retum the response rate to control levels while Example 1 still displays complete 5-HT1p antagonist effects. By four hours post-administration (Column 4), the 5-HTqa antagonist effects of Compounds A and B are completely lost, while Example 1 continues to provide complete antagonism of the agonist-induced decrease in response rate. Thus, the duration of action of Example 1 is longer than 4 hours, while those of Compounds A and B are somewhere between 30 minutes and 2 hours.
The increased duration of action of the novel compounds of the present invention, compared to that of the classes of compounds disclosed in U.S. Patent No. 6,127,357 and WO 97/03892 is particularly advantageous in that a smaller number of . doses of the compound can be administered to produce a similar therapeutic effect.
Compounds of the present invention may be used to treat a subject suffering from CNS disorders such as schizophrenia, (and other psychotic disorders such as paranoia and mano-depressive illness), Parkinson's disease and other motor
® WO 02/44142 PCT/US01/43160 disorders, anxiety (e.g. generalized anxiety disorders, panic attacks, and obsessive compulsive disorders), depression (such as by the potentiation of serotonin reuptake inhibitors and serotonin norepinephrine reuptake inhibitors), Tourette's syndrome, ‘ migraine, autism, attention deficit disorders and hyperactivity disorders. Compounds
S of the present invention may also be useful for the treatment of sleep disorders, social - phobias, pain, thermoregulatory disorders, endocrine disorders, urinary incontinence, vasospasm, stroke, eating disorders such as for example obesity, anorexia and : bulimia, sexual dysfunction, and the treatment of alcohol, drug and nicotine withdrawal.
Compounds of the present invention are also useful for the treatment of . cognitive dysfunction. Thus, compounds of the present invention may be useful for the treatment of cognitive dysfunction associated with mild cognitive impairment (MCI)) Alzheimer's disease and other dementias including Lewy Body, vascular, and post stroke dementias. Cognitive dysfunction associated with surgical procedures, traumatic brain injury or stroke may also be treated in accordance with the present invention. Further, compounds of the present invention may be useful for the treatment of diseases in which cognitive dysfunction is a co-morbidity such as, for example, Parkinson's disease, autism and attention deficit disorders. “Provided”, as used herein with respect to providing a compound or substance covered by this invention, means either directly administering such a compound or ’ substance, or administering a prodrug, derivative, or analog which will form an effective amount of the compound or substance within the body. Prodrugs can be prepared such as described in Design of Prodrugs, Bundgaard, H. ed., (Elsevier, New York 1985); Prodrugs as Novel Drug Delivery Systems, Higuchi, T and Stella, V. eds, (American Chemical Society, Washington, D.C. 1975); Design of Biopharmaceutical
Properties through Prodrugs and Analogs, Roche, E. ed., (American Pharmaceutical
Association Academy of Pharmaceutical Sciences, Washington, D.C., 1977); and
Metabolic Considerations in Prodrug Design, Balant, L.P. and Doelker, E. in Burger's
Medicinal Chemistry amd Drug Discovery, Fifth Edition, Wolff, M., ed, Volume 1, pages ’ 949-982, (John Wiley & Sons, Inc. 1995).
J 02/44142 PCT/USO1/43160
The compounds of the present invention may be administered orally or parentally, neat or in combination with conventional pharmaceutical carriers.
Applicable solid carriers can include one or more substances which may also act as flavoring agents, lubricants, solubilizers, suspending agents, fillers, glidants, compression aids, binders, tablet-disintegrating agents or encapsulating materials. In powders, the carrier is a finely divided solid which is in admixture with the finely divided active ingredient. In tablets, the active ingredient is mixed with a carrier having the necessary compression properties in suitable proportions and compacted in the shape and size desired. The powders and tablets may contain up to 99% of the active ingredient. Suitable solid carriers include, for example, calcium phosphate, magnesium stearate, talc, sugars, lactose, dextrin, starch, gelatin, cellulose, methyl cellulose, sodium carboxymethyl cellulose, polyvinylpyrrolidine, low melting waxes and ion exchange resins. Liquid carriers may be used in preparing solutions, suspensions, emulsions, syrups and elixirs. The active ingredient of this invention can be dissolved or suspended in a pharmaceutically acceptable liquid carrier such as water, an organic solvent, a mixture of both or pharmaceutically acceptable oils or fat.
The liquid carrier can contain other suitable pharmaceutical additives such as solubilizers, emulsifiers, buffers, preservatives, sweeteners, flavoring agents, suspending agents, thickening agents, colors, viscosity regulators, stabilizers or osmo-regulators. Suitable examples of liquid carriers for oral and parenteral administration include water (particularly containing additives as above, e.g., cellulose derivatives, preferably sodium carboxymethyl cellulose solution), alcohols (including monohydric alcohols and polyhydric alcohols, e.g., glycols) and their derivatives, and oils (e.g., fractionated coconut oil and arachis oil). For parenteral administration the carrier can also be an oily ester such as ethyl oleate and isopropyl myristate. Sterile liquid carriers are used in sterile liquid form compositions for parenteral administration. Liquid pharmaceutical compositions which are sterile solutions or suspensions can be utilized by, for example, intramuscular, intraperitoneal or subcutaneous injection. Sterile solutions can also be administered intravenously.
Oral administration may be either in liquid or solid composition form. Preferably, the pharmaceutical compositions containing the present compounds are in unit dosage form, e.g., as tablets or capsules. In such form, the composition is sub-divided in unit dosages containing appropriate quantities of the active ingredients. The unit dosage forms can be packaged compositions, for example, packaged powders, vials,
Claims (51)
1. A compound according to formula (111): AS CHa =N R4 Ort 0; (nr wherein Ry is cyano, nitro, trifluoromethyl or halogen, or pharmaceutically acceptable acid addition salts thereof.
2. A compound of Claim 1 wherein R; is cyano.
3. A compound which is 4-Cyano-N-{2-[4-(2,3-dihydro-benzo[1,4]dioxin-5-yl)- piperazin-1-yl]-propyl}-N-pyridin-2-yl-benzamide, or its pharmaceutically acceptable acid addition salts.
4. A compound which is (R)-4-Cyano-N-{2-[4-(2,3-dihydro-benzo[1,4]dioxin-5-yl)- piperazin-1-yl}-propyl}-N-pyridin-2-yl-benzamide hydrochloride.
5. A compound according to any one of Claims 1 to 4 in which the R-isomer is in enantiomeric excess of the S-isomer.
6. A compound according to any one of Claims 1 to 5 which is made up of about 90% or more by weight R-isomer and about 10% or less by weight S isomer.
7 A compound according to any one of Claims 1 to 5 which is made up of about 99% by weight R-isomer and about 1% by weight S isomer.
8. A compound which is (R)-4-Cyano-N-{2-[4-(2,3-dihydro-benzo[1,4]dioxin-5-yl)- piperazin-1-yl}-propyl}-N-pyridin-2-yl-benzamide, or its pharmaceutically acceptable acid addition salt, substantially free of its (S) stereoisomer. CLEAN COPY
PCT/US01/43160 ® te
9. A compound as claimed in any one of Claims 1 to 8 which is in the form of a salt with hydrochloric acid.
10. A pharmaceutical composition comprising a compound or pharmaceutically acceptable salt thereof as claimed in any one of Claims 1 to 9, and a pharmaceutically acceptable carrier or excipient.
11. A pharmaceutical composition comprising (R)-4-Cyano-N-{2-[4-(2,3-dihydro- benzo[1,4]dioxin-5-yl)-piperazin-1-yl]-propyl}-N-pyridin-2-yl-benzamide, or its pharmaceutically acceptable acid addition salt, substantially free of its (S) stereoisomer, and a pharmaceutically acceptable carrier or excipient.
12. Use of a compound or pharmaceutically acceptable salt thereof as claimed in any one of Claims 1 to 9 in the preparation of a medicament for treating a patient suffering from a CNS disorder.
13. Use of a compound or pharmaceutically acceptable salt thereof as claimed in any one of Claims 1 to 9 in the preparation of a medicament for treating anxiety or depression in a patient.
14. Use of a compound or pharmaceutically acceptable salt thereof as claimed in any one of Claims 1 to 9 in the preparation of a medicament for treating schizophrenia in a patient.
15. Use of a compound or pharmaceutically acceptable salt thereof as claimed in any one of Claims 1 to 9 in the preparation of a medicament for treating memory deficits or cognitive dysfunction in a patient.
16. Use of a compound or pharmaceutically acceptable salt thereof as claimed in any one of Claims 1 to 9 in the preparation of a medicament for treating alcohol, nicotine and drug withdrawal in a patient. AMENDED SHEET
PCT/US01/43160 J 7
17. Use of a compound or pharmaceutically acceptable salt thereof as claimed in any one of Claims 1 to 9 in the preparation of a medicament for treating Parkinson’s disease and motor disorders in a patient.
18. Use of a compound or pharmaceutically acceptable salt thereof as claimed in any one of Claims 1 to 9 in the preparation of a medicament for treating migraine in a patient.
19. Use of a compound or pharmaceutically acceptable salt thereof as claimed in any one of Claims 1 to 9 in the preparation of a medicament for treating eating disorders in a patient.
20. Use of a compound or pharmaceutically acceptable salt thereof as claimed in any one of Claims 1 to 9 in the preparation of a medicament for treating sexual dysfunction in a patient.
21. Use of a compound or pharmaceutically acceptable salt thereof as claimed in any one of Claims 1 to 9 in the preparation of a medicament for treating urinary incontinence in a patient.
22. Use of a compound or pharmaceutically acceptable salt thereof as claimed in any one of Claims 1 to 9 in the preparation of a medicament for treating stroke in a patient.
23. Use of a compound or pharmaceutically acceptable salt thereof as claimed in any one of Claims 1 to 9 in the preparation of a medicament for treating endocrine disorders in a patient.
24. Use of a compound or pharmaceutically acceptable salt thereof as claimed in any one of Claims 1 to 9 in the preparation of a medicament for treating sleep disorders in a patient. AMENDED SHEET
PCT/US01/43160 o 18- Use of a compound or pharmaceutically acceptable salt thereof as claimed in any one of Claims 1 to 9 in the preparation of a medicament for treating attention deficit disorders in a patient.
26. Use of a compound or pharmaceutically acceptable salt thereof as claimed in any one of Claims 1 to 9 in the preparation of a medicament for treating Tourette's syndrome, autism, social phobias, hyperactivity disorders or thermoregulatory disorders in a patient.
27. A compound as claimed in any one of claims 1 to 9 for use as a pharmaceutical.
28. A process for preparing a compound as claimed in claim 1 which comprises one of the following: a) acylating a compound of formula (IV): i AS CH, ~N ot (IV) using an acylating agent containing the moiety pes O wherein R, is as defined in claim 1; or AMENDED SHEET
PCT/US01/43160 @ 1e- b) alkylating an amide or thioamide of formula (V1) IAN ~N w—n—co—{ Hr, (Vi) (where R; is defined above) with an alkylating agent (e.g halide or tosylate) providing the group of formula (Vii) /N\ 0) 0] —\ C \_/ ~~ (vn) or c) alkylating a compound of formula (Vil 0] Oo N NH (VII) with a compound of formula (1X) X ~N CH3 A v—eo—d Hr X CLEAN COPY
PCT/US01/43160 0 5 (IX) (where R, is as defined above and X is a leaving group) or d) heteroarylating a compound of formula (X) 0] 0 CHs N N \__/ (X) (where R; is as defined above) with a compound providing the 2-pyridyl group; or e) reacting a piperazine compound of formula AN ~N S\N ( wp neo Hr (where R; is as defined above) with a fluoro compound of formula 0] Oo 8 ] or f) converting a basic compound of formula (lll) as defined in Claim 1 to a pharmaceutically acceptable acid addition sait thereof or vice versa; or AMENDED SHEET
@ -21- PCT/US01/43160 g) resolving a racemic compound of formula (lll) to give an enantiomeric excess of the R form over the S form, or vice versa.
29. Use of a compound as claimed in any one of claims 1 to 9 in the manufacture of a medicament for use in a method of treatment.
30. A substance or composition for use in a method for treating a patient suffering from a CNS disorder, said substance or composition comprising a compound or pharmaceutically acceptable salt thereof as claimed in any one of Claims 1 to 9, and said method comprising administering said substance or composition.
31. A substance or composition for use in a method for treating anxiety or depression in a patient, said substance or composition comprising acompound or pharmaceutically acceptable salt thereof as claimed in any one of Claims 1 to 9, and said method comprising administering said substance or composition.
32. A substance or composition for use in a method for treating schizophrenia in a patient, said substance or composition comprising a compound or pharmaceutically acceptable salt thereof as claimed in any one of Claims 1 to 9, and said method comprising administering said substance or composition.
33. A substance or composition for use in a method for treating memory deficits or cognitive dysfunction in a patient, said substance or composition comprising a compound or pharmaceutically acceptable salt thereof as claimed in any one of Claims 1 to 9, and said method comprising administering said substance or composition.
34. A substance or composition for use in a method for treating alcohol, AMENDED SHEET
@® -22- PCT/US01/43160 nicotine and drug withdrawal in a patient, said substance or composition comprising a compound or pharmaceutically acceptable salt thereof as claimed in any one of Claims 1 to 9, and said method comprising administering said substance or composition.
35. A substance or composition for use in a method for treating Parkinson’s disease and motor disorders in a patient, said substance or composition comprising a compound or pharmaceutically acceptable salt thereof as claimed in any one of Claims 1 to 9, and said method comprising administering said substance or composition.
36. A substance or composition for use in a method for treating migraine in a patient, said substance or composition comprising a compound or pharmaceutically acceptable salt thereof as claimed in any one of Claims 1 to 9, and said method comprising administering said substance or composition.
37. A substance or composition for use in a method for treating eating disorders in a patient, said substance or composition comprising a compound or pharmaceutically acceptable salt thereof as claimed in any one of Claims 1 to 9, and said method comprising administering said substance or composition.
38. A substance or composition for use in a method for treating sexual dysfunction in a patient, said substance or composition comprising a compound or pharmaceutically acceptable salt thereof as claimed in any one of Claims 1 to 9, and said method comprising administering said substance or composition.
39. A substance or composition for use in a method for treating urinary incontinence in a patient, said substance or composition comprising a compound or pharmaceutically acceptable salt thereof as claimed in any one AMENDED SHEET
@ -23- PCT/USQ01/43160 of Claims 1 to 9, and said method comprising administering said substance or composition.
40. A substance or composition for use in a method for treating stroke in a patient, said substance or composition comprising a compound or pharmaceutically acceptable salt thereof as claimed in any one of Claims 1 to 9, and said method comprising administering said substance or composition.
41. A substance or composition for use in a method for treating endocrine disorders in a patient, said substance or composition comprising a compound or pharmaceutically acceptable salt thereof as claimed in any one of Claims 1 to 9, and said method comprising administering said substance or composition.
42. A substance or composition for use in a method for treating sleep disorders in a patient, said substance or composition comprising a compound or pharmaceutically acceptable salt thereof as claimed in any one of Claims 1 to 9, and said method comprising administering said substance or composition.
43. A substance or composition for use in a method for treating attention deficit disorders in a patient, said substance or composition comprising a compound or pharmaceutically acceptable salt thereof as claimed in any one of Claims 1 to 9, and said method comprising administering said substance or composition.
44. A substance or composition for use in a method for treating Tourette's syndrome, autism, social phobias, hyperactivity disorders or thermoregulatory disorders in a patient, said substance or composition comprising a compound or pharmaceutically acceptable salt thereof as claimed in any one of Claims 1 to 9, and said method comprising administering said substance or AMENDED SHEET
® -24- PCT/US01/43160 composition.
45. A substance or composition for use in a method of treatment, said substance or composition comprising a compound as claimed in any one of Claims 1 to 9, and said method comprising administering said substance or composition.
46. A compound according to any one of Claims 1 to 9 or 27, substantially as herein described and illustrated.
47. A composition according to Claim 10 or Claim 11, substantially as herein described and illustrated.
48. Use according to any one of Claims 12 to 26 or 29, substantially as herein described and illustrated.
49. A process according to Claim 28, substantially as herein described and illustrated.
50. A substance or composition for use in a method of treatment according to any one of Claims 30 to 45, substantially as herein described and illustrated.
51. A new compound, a hew composition, a new use of a compound as claimed in any one of Claims 1 to 9, a new process for preparing a compound, or a substance or composition for a new use in a method of treatment, substantially as herein described. AMENDED SHEET
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US25330100P | 2000-11-28 | 2000-11-28 |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200304994B true ZA200304994B (en) | 2004-10-04 |
Family
ID=34572567
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200304994A ZA200304994B (en) | 2000-11-28 | 2003-06-26 | Piperazine derivatives, their preparation and their use for treating central nervous systems (CNS) disorders. |
Country Status (1)
Country | Link |
---|---|
ZA (1) | ZA200304994B (en) |
-
2003
- 2003-06-26 ZA ZA200304994A patent/ZA200304994B/en unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2428039C (en) | Serotonergic agents | |
AU2002237654A1 (en) | Piperazine derivatives, their preparation and their use for treating central nervous system (CNS) disorders | |
JP3940359B2 (en) | Compound | |
US7189713B2 (en) | Piperidine derivatives | |
EP3768260A1 (en) | Oxadiazole transient receptor potential channel inhibitors | |
JP6203841B2 (en) | Carbamate / urea derivatives | |
DE69617995T2 (en) | INDOLALKYL DERIVATIVES OF BENZODIOXANMENTHYLAMINE AS 5-HT1A RECEPTOR LIGANDS | |
PL176051B1 (en) | Application of dimethylbezofuranes and dimethylbenzopyranes as antagonists of 5-ht 3 | |
US7816362B2 (en) | Serotonergic agents | |
ZA200304994B (en) | Piperazine derivatives, their preparation and their use for treating central nervous systems (CNS) disorders. | |
JP2021104931A (en) | Dibenzoazepine derivative having nitrogen-containing heterocycle | |
JPH037229A (en) | Cerebral nerve function improver | |
WO2014128223A1 (en) | Pyridine derivatives as 5-ht6 receptor antagonists | |
MXPA05002740A (en) | Antidepressant cycloalkylamine derivatives of 2,3-dihydro-1,4-benzodioxan. | |
KR20240035517A (en) | Hydrogenated Quinoxaline | |
WO2002090327A1 (en) | Piperazinyl-isatins | |
JP2002519350A (en) | 6- (4-arylalkylpiperazin-1-yl) benzodioxane and 6- (4-arylalkylpiperazin-1-yl) chroman derivatives: dopamine receptor subtype specific ligands | |
JP2016106072A (en) | Propellane derivative | |
MXPA00010456A (en) | Serotonergic agents |